Change search
ReferencesLink to record
Permanent link

Direct link
European Adrenal Insufficiency Registry (EU-AIR): a comparative observational study of glucocorticoid replacement therapy
Linköping University, Department of Medical and Health Sciences, Division of Cardiovascular Medicine. Linköping University, Faculty of Health Sciences. Östergötlands Läns Landsting, Heart and Medicine Center, Department of Nephrology.
ViroPharma Incorporated, Exton, Pennsylvania, USA .
ViroPharma SPRL, Maidenhead, UK .
St James’s University Hospital, Leeds, UK .
Show others and affiliations
2014 (English)In: BMC Endocrine Disorders, ISSN 1472-6823, Vol. 14, no 40Article in journal (Refereed) Published
Abstract [en]


Increased morbidity and mortality associated with conventional glucocorticoid replacement therapy for primary adrenal insufficiency (primary AI; estimated prevalence 93-140/million), secondary AI (estimated prevalence, 150-280/million, respectively) or congenital adrenal hyperplasia (estimated prevalence, approximately 65/million) may be due to the inability of typical glucocorticoid treatment regimens to reproduce the normal circadian profile of plasma cortisol. A once-daily modified-release formulation of hydrocortisone has been developed to provide a plasma cortisol profile that better mimics the daytime endogenous profile of cortisol. Here, we describe the protocol for the European Adrenal Insufficiency Registry (EU-AIR), an observational study to assess the long-term safety of modified-release hydrocortisone compared with conventional glucocorticoid replacement therapies in routine clinical practice ( identifier: NCT01661387).


Patients enrolled in EU-AIR have primary or secondary AI and are receiving either modified-release or conventional glucocorticoid replacement therapy. The primary endpoints of EU-AIR are the incidence of intercurrent illness, adrenal crisis and serious adverse events (SAEs), as well as the duration of SAEs and dose changes related to SAEs. Data relating to morbidity, mortality, adverse drug reactions, dosing and concomitant therapies will be collected. Patient diaries will record illness-related dose changes between visits. All decisions concerning medical care are made by the registry physician and patient. Enrolment is targeted at achieving 3600 patient-years of treatment (1800 patient-years per group) for the primary analysis, which is focused on determining the non-inferiority of once-daily modified-release replacement therapy compared with conventional glucocorticoid therapy.


Recruitment began in August 2012 and, as of March 2014, 801 patients have been enrolled. Fifteen centres are participating in Germany, the UK and Sweden, with recruitment soon to be initiated in the Netherlands.


EU-AIR will provide a unique opportunity not only to collect long-term safety data on a modified-release preparation of glucocorticoid but also to evaluate baseline data on conventional glucocorticoid replacement. Such data should help to improve the treatment of AI.

Place, publisher, year, edition, pages
BioMed Central, 2014. Vol. 14, no 40
National Category
Clinical Medicine
URN: urn:nbn:se:liu:diva-109287DOI: 10.1186/1472-6823-14-40ISI: 000338366200001PubMedID: 24884782OAI: diva2:737055
Available from: 2014-08-11 Created: 2014-08-11 Last updated: 2015-04-01Bibliographically approved

Open Access in DiVA

fulltext(295 kB)42 downloads
File information
File name FULLTEXT01.pdfFile size 295 kBChecksum SHA-512
Type fulltextMimetype application/pdf

Other links

Publisher's full textPubMed

Search in DiVA

By author/editor
Ekman, Bertil
By organisation
Division of Cardiovascular MedicineFaculty of Health SciencesDepartment of Nephrology
In the same journal
BMC Endocrine Disorders
Clinical Medicine

Search outside of DiVA

GoogleGoogle Scholar
Total: 42 downloads
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 66 hits
ReferencesLink to record
Permanent link

Direct link